Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
161 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
H1N1 Infection - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘H1N1 Infection - Pipeline Review, H1 2015’, provides an overview of the H1N1 Infection’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for H1N1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H1N1 Infection and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of H1N1 Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H1N1 Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H1N1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H1N1 Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for H1N1 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 H1N1 Infection Overview 8 Therapeutics Development 9 Pipeline Products for H1N1 Infection - Overview 9 Pipeline Products for H1N1 Infection - Comparative Analysis 10 H1N1 Infection - Therapeutics under Development by Companies 11 H1N1 Infection - Therapeutics under Investigation by Universities/Institutes 15 H1N1 Infection - Pipeline Products Glance 17 Clinical Stage Products 17 Early Stage Products 18 H1N1 Infection - Products under Development by Companies 19 H1N1 Infection - Products under Investigation by Universities/Institutes 22 H1N1 Infection - Companies Involved in Therapeutics Development 23 Adamas Pharmaceuticals, Inc. 23 Akshaya Bio Inc. 24 AlphaVax, Inc. 25 Antigen Express, Inc. 26 Beijing Minhai Biotechnology Co., Ltd 27 Bionor Pharma ASA 28 CEL-SCI Corporation 29 Cilian AG 30 Colby Pharmaceutical Company 31 Crucell N.V. 32 EpiVax, Inc. 33 Etubics Corporation 34 Gemmus Pharma Inc. 35 iBio, Inc. 36 Inovio Pharmaceuticals, Inc. 37 Johnson & Johnson 38 Kineta, Inc. 39 Kyowa Hakko Kirin Co., Ltd. 40 Medicago Inc. 41 NanoViricides, Inc. 42 Onxeo SA 43 OPKO Health, Inc. 44 REPLICor Inc. 45 Revivicor, Inc. 46 Sarepta Therapeutics, Inc. 47 Sirnaomics, Inc. 48 TaiMed Biologics Inc. 49 Takeda Pharmaceutical Company Limited 50 TechnoVax, Inc. 51 Vaxart, Inc. 52 Vaxin, Inc. 53 Vaxine Pty Ltd 54 H1N1 Infection - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Combination Products 56 Assessment by Target 57 Assessment by Mechanism of Action 59 Assessment by Route of Administration 61 Assessment by Molecule Type 63 Drug Profiles 65 ADS-324 - Drug Profile 65 AEA-35p - Drug Profile 66 Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza - Drug Profile 67 Aspidasept - Drug Profile 68 BA-032 - Drug Profile 69 C-05 - Drug Profile 70 CiFlu - Drug Profile 71 CR-9114 - Drug Profile 73 CYM-5442 - Drug Profile 74 diridavumab - Drug Profile 75 FVH-1 - Drug Profile 77 Gamma-Flu - Drug Profile 78 GP-1001 - Drug Profile 79 GP-1681 - Drug Profile 80 GREFLU/CAL - Drug Profile 82 H1N1 [A/Aichi/2/68] vaccine - Drug Profile 83 Human Antibody Based Vaccines - Drug Profile 84 Influ-nRNA - Drug Profile 86 influenza (strain H5N1, H1N1) vaccine - Drug Profile 87 influenza [H1N1] (quadrivalent) virus like particle vaccine - Drug Profile 88 influenza [H1N1] vaccine - Drug Profile 90 influenza [strain A/H1N1] vaccine - Drug Profile 91 influenza [strain H1N1] (mutivalent) vaccine - Drug Profile 92 influenza [strain H1N1] vaccine - Drug Profile 93 influenza A vaccine - Drug Profile 94 influenza vaccine - Drug Profile 95 influenza vaccine - Drug Profile 96 influenza vaccine - Drug Profile 98 influenza vaccine [H1N1] - Drug Profile 99 Innate Immune Agonists - Drug Profile 101 INO-3401 - Drug Profile 102 INO-3510 - Drug Profile 103 INO-3605 - Drug Profile 104 INO-3609 - Drug Profile 105 JVRS-100 + influenza [H1N1/H3N2] vaccine - Drug Profile 106 LEAPS-H1N1-DC - Drug Profile 107 NVINF-1 - Drug Profile 108 NVINF-2 - Drug Profile 110 pandemic influenza [H1N1] (monovalent) vaccine - Drug Profile 111 pandemic influenza [H5N1/H1N1] vaccine - Drug Profile 112 pandemic influenza vaccine [H1N1] - Drug Profile 113 radavirsen - Drug Profile 114 REP-9 - Drug Profile 116 RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection - Drug Profile 117 Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile 118 STP-702 - Drug Profile 119 Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 120 TMB-571 - Drug Profile 121 TVX-002 - Drug Profile 122 Vacc-Flu - Drug Profile 123 Vaccine to Target TLR2 for Infectious Disease - Drug Profile 124 VH-244 - Drug Profile 125 VX-787 - Drug Profile 127 VXAA-1.1 - Drug Profile 128 Z-3G1 - Drug Profile 129 H1N1 Infection - Recent Pipeline Updates 130 H1N1 Infection - Dormant Projects 143 H1N1 Infection - Product Development Milestones 146 Featured News & Press Releases 146 Appendix 156 Methodology 156 Coverage 156 Secondary Research 156 Primary Research 156 Expert Panel Validation 156 Contact Us 156 Disclaimer 157
List of Tables Number of Products under Development for H1N1 Infection, H1 2015 13 Number of Products under Development for H1N1 Infection - Comparative Analysis, H1 2015 14 Number of Products under Development by Companies, H1 2015 16 Number of Products under Development by Companies, H1 2015 (Contd..1) 17 Number of Products under Development by Companies, H1 2015 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H1 2015 20 Comparative Analysis by Clinical Stage Development, H1 2015 21 Comparative Analysis by Early Stage Development, H1 2015 22 Products under Development by Companies, H1 2015 23 Products under Development by Companies, H1 2015 (Contd..1) 24 Products under Development by Companies, H1 2015 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2015 26 H1N1 Infection - Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 27 H1N1 Infection - Pipeline by Akshaya Bio Inc., H1 2015 28 H1N1 Infection - Pipeline by AlphaVax, Inc., H1 2015 29 H1N1 Infection - Pipeline by Antigen Express, Inc., H1 2015 30 H1N1 Infection - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 31 H1N1 Infection - Pipeline by Bionor Pharma ASA, H1 2015 32 H1N1 Infection - Pipeline by CEL-SCI Corporation, H1 2015 33 H1N1 Infection - Pipeline by Cilian AG, H1 2015 34 H1N1 Infection - Pipeline by Colby Pharmaceutical Company, H1 2015 35 H1N1 Infection - Pipeline by Crucell N.V., H1 2015 36 H1N1 Infection - Pipeline by EpiVax, Inc., H1 2015 37 H1N1 Infection - Pipeline by Etubics Corporation, H1 2015 38 H1N1 Infection - Pipeline by Gemmus Pharma Inc., H1 2015 39 H1N1 Infection - Pipeline by iBio, Inc., H1 2015 40 H1N1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 41 H1N1 Infection - Pipeline by Johnson & Johnson, H1 2015 42 H1N1 Infection - Pipeline by Kineta, Inc., H1 2015 43 H1N1 Infection - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 44 H1N1 Infection - Pipeline by Medicago Inc., H1 2015 45 H1N1 Infection - Pipeline by NanoViricides, Inc., H1 2015 46 H1N1 Infection - Pipeline by Onxeo SA, H1 2015 47 H1N1 Infection - Pipeline by OPKO Health, Inc., H1 2015 48 H1N1 Infection - Pipeline by REPLICor Inc., H1 2015 49 H1N1 Infection - Pipeline by Revivicor, Inc., H1 2015 50 H1N1 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2015 51 H1N1 Infection - Pipeline by Sirnaomics, Inc., H1 2015 52 H1N1 Infection - Pipeline by TaiMed Biologics Inc., H1 2015 53 H1N1 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 54 H1N1 Infection - Pipeline by TechnoVax, Inc., H1 2015 55 H1N1 Infection - Pipeline by Vaxart, Inc., H1 2015 56 H1N1 Infection - Pipeline by Vaxin, Inc., H1 2015 57 H1N1 Infection - Pipeline by Vaxine Pty Ltd, H1 2015 58 Assessment by Monotherapy Products, H1 2015 59 Assessment by Combination Products, H1 2015 60 Number of Products by Stage and Target, H1 2015 62 Number of Products by Stage and Mechanism of Action, H1 2015 64 Number of Products by Stage and Route of Administration, H1 2015 66 Number of Products by Stage and Molecule Type, H1 2015 68 H1N1 Infection Therapeutics - Recent Pipeline Updates, H1 2015 134 H1N1 Infection - Dormant Projects, H1 2015 147 H1N1 Infection - Dormant Projects (Contd..1), H1 2015 148 H1N1 Infection - Dormant Projects (Contd..2), H1 2015 149
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
